Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Jaundice, Obstructive D041781 2 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Leukemia, Eosinophilic, Acute D015472 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Subacute Sclerosing Panencephalitis D013344 3 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Toxemia D014115 3 associated lipids
Contracture D003286 3 associated lipids
Bronchial Diseases D001982 3 associated lipids
Pneumonia, Pneumococcal D011018 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Oxholm P and Winther K Thrombocyte involvement in immune inflammatory reactions. 1986 Allergy pmid:3515999
Kurosawa M et al. Increased levels of blood platelet-activating factor in bronchial asthmatic patients with active symptoms. 1994 Allergy pmid:8198242
Mishra RK et al. Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K). 2005 Allergy pmid:16076309
Mullol J et al. Update on rupatadine in the management of allergic disorders. 2015 Allergy pmid:25491409
Egesten A and Malm J Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C. 1998 Allergy pmid:9860239
Howarth PH Mediators of nasal blockage in allergic rhinitis. 1997 Allergy pmid:9353555
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Dunoyer-Geindre S et al. PAF acether release on antigenic challenge. A method for the investigation of drug allergic reactions. 1992 Allergy pmid:1590567
Juhlin L A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. 1995 Allergy pmid:7645678
Meltzer EO The use of anti-H1 drugs in mild asthma. 1995 Allergy pmid:7645681
Takafuji S et al. Effects of interleukin (IL)-3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a. 1996 Allergy pmid:8874660
Di Leo E et al. Treatment of acquired cold urticaria with rupatadine. 2009 Allergy pmid:19392988
Takafuji S et al. Release of granule proteins from human eosinophils stimulated with mast-cell mediators. 1998 Allergy pmid:9821474
Maniscalco M et al. The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. 2000 Allergy pmid:10955702
Leggieri E et al. Study of the effects of paf-acether on human nasal airways. 1991 Allergy pmid:1720286
Mukai K et al. New insights into the roles for basophils in acute and chronic allergy. 2009 Allergol Int pmid:19153532
Negro Alvarez JM et al. Platelet-activating factor antagonists. 1997 Sep-Oct Allergol Immunopathol (Madr) pmid:9395010
Monteseirín J et al. Formation of lipids, peptides and cytokines. 1996 Sep-Oct Allergol Immunopathol (Madr) pmid:8985477
Miadonna A et al. Induction and control of allergic inflammation in human respiratory airways. 1993 May-Jun Allergol Immunopathol (Madr) pmid:7689291
Rihoux JP [Allergic reaction and vascular permeability]. 1990 Allerg Immunol (Paris) pmid:2288644
Beauvais F and Benveniste J [IgE and anaphylaxis mediators]. 1987 Allerg Immunol (Paris) pmid:2968802
Mencia-Huerta JM et al. [Effect of long-term administration of platelet activating factor on pulmonary response and morphology in the guinea pig]. 1988 Allerg Immunol (Paris) pmid:3245884
Ligumsky M et al. The role of platelet activating factor [correction of actor] in acute gastric injury and its protection by sucralfate. 1990 Aliment. Pharmacol. Ther. pmid:2129638
Greenberg SS et al. Ethanol suppresses endotoxin but not platelet activating factor-induced hypotension and nitric oxide. 1996 Alcohol. Clin. Exp. Res. pmid:8904980
Saleh AA et al. Effect of alcohol on platelet-activating factor acetylhydrolase activity in pregnant and nonpregnant mice. 1994 Alcohol. Clin. Exp. Res. pmid:7978079
Baker RC et al. Effects of ethanol on human platelets stimulated with platelet-activating factor, a biologically active ether phospholipid. 1989 Alcohol. Clin. Exp. Res. pmid:2557776
Lands WE Cellular signals in alcohol-induced liver injury: a review. 1995 Alcohol. Clin. Exp. Res. pmid:7485841
Kelesidis T et al. The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. AIDS Rev pmid:26616844
Chini M et al. Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. 2012 AIDS Res. Hum. Retroviruses pmid:22050695
Lima RG et al. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. 2006 AIDS Res. Hum. Retroviruses pmid:16910832
Tsoupras AB et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? 2008 AIDS Res. Hum. Retroviruses pmid:18620493
Rink TJ Stimulus-response coupling mechanisms in human platelets. 1986 Agents Actions Suppl. pmid:3028101
Baroggi N et al. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. 1986 Agents Actions Suppl. pmid:3028108
Parnham MJ et al. Regulation of the oxidative burst of macrophages by lipid mediators. 1984 Agents Actions Suppl. pmid:6433680
Alabaster VA et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. 1991 Agents Actions Suppl. pmid:1793066
Heuer HO The effects of hetrazepine PAF antagonists in preclinical models of asthma. 1991 Agents Actions Suppl. pmid:1793067
Mazzoni L et al. Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. 1991 Agents Actions Suppl. pmid:1793069
Billah MM et al. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. 1991 Agents Actions Suppl. pmid:1793070
Saeed SA et al. Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. 1991 Agents Actions Suppl. pmid:1793071
Page CP and Spina D The therapeutic relevance of PAF antagonists. 1989 Agents Actions Suppl. pmid:2683635
Braquet P et al. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021. 1987 Agents Actions Suppl. pmid:3314418
Mest HJ et al. Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. 1992 Agents Actions Suppl. pmid:1632298
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Koltai M and Braquet PG Involvement of PAF in atherogenesis. Brief review. 1992 Agents Actions Suppl. pmid:1632308
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Morley J et al. Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. 1988 Agents Actions Suppl. pmid:3262989
McMillan RM and Carter GW Design and development of drugs. 1991 Agents Actions Suppl. pmid:1664186
Guinot P et al. Effects of BN 52063 on PAF-acether induced weal and flare in man. 1987 Agents Actions Suppl. pmid:3479000
Lang M et al. Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. 1987 Agents Actions Suppl. pmid:3479001
Codde JP et al. Effects of altered prostanoid and lyso-PAF synthesis by marine oil diets on blood pressure of salt loaded spontaneously hypertensive rats. 1987 Agents Actions Suppl. pmid:3481207